GLP-1 and GIP: reading the semaglutide–tirzepatide comparison
A receptor count cannot rank a medicine. Current US labels and the SURMOUNT-5 trial show why product, population and outcome must stay attached to every comparison.
Follow a thread
1 story found Clear filters ↗
A receptor count cannot rank a medicine. Current US labels and the SURMOUNT-5 trial show why product, population and outcome must stay attached to every comparison.